LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Neurocrine Biosciences Inc

Closed

SectorHealthcare

143.98 0.22

Overview

Share price change

24h

Current

Min

141.47

Max

144.1

Key metrics

By Trading Economics

Income

100M

108M

Sales

115M

688M

P/E

Sector Avg

41.302

35.733

EPS

0.7

Profit margin

15.636

Employees

1,800

EBITDA

143M

167M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+16.01% upside

Dividends

By Dow Jones

Next Earnings

29 Oct 2025

Market Stats

By TradingEconomics

Market Cap

613M

14B

Previous open

143.76

Previous close

143.98

News Sentiment

By Acuity

95%

5%

359 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Neurocrine Biosciences Inc Chart

Past performance is not a reliable indicator of future results.

Related News

28 Jan 2025, 00:03 UTC

Hot Stocks

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

14 Mar 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Peer Comparison

Price change

Neurocrine Biosciences Inc Forecast

Price Target

By TipRanks

16.01% upside

12 Months Forecast

Average 167.17 USD  16.01%

High 200 USD

Low 124 USD

Based on 24 Wall Street analysts offering 12 month price targets forNeurocrine Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

24 ratings

21

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

109.55 / 121.61Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

359 / 371 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
help-icon Live chat